Successful treatment with tralokinumab in patients with atopic dermatitis and dupilumab-induced psoriasis

L Quattrini^{1

2}, G Caldarola^{1

2}, G M Falco^{1

2}, L M Pinto^{1

2}, K Peris^{1

2}

Affiliations

¹ Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
² UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.

L Quattrini et al. J Eur Acad Dermatol Venereol. 2023 Dec.

. 2023 Dec;37(12):e1432-e1434.

doi: 10.1111/jdv.19351. Epub 2023 Jul 24.

L Quattrini^{1

2}, G Caldarola^{1

2}, G M Falco^{1

2}, L M Pinto^{1

2}, K Peris^{1

2}

¹ Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
² UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.

No abstract available

References

1. Schlösser AR, Shareef M, Olydam J, Nijsten TEC, Hijnen DJ. Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice. 2023;1-8.
1. Ms CMB, Bs MHP, Zirwas MJ. Development of psoriasis during treatment with dupilumab: a systematic review. J Am Dermatol. 2022;86(3):708-709.
1. Parker JJ, Sugarman JL, Silverberg NB, Gonzalez ME, Ramien ML, Teng JMC, et al. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children. Pediatr Dermatol. 2021;38(6):1500-1505.
1. Eyerich S, Onken AT, Weidinger S, Franke A, Nasorri F, Pennino D, et al. Mutual antagonism of T cells causing psoriasis and atopic eczema. N Engl J Med. 2011;365(3):231-238.
1. Bridgewood C, Wittmann M, Macleod T, Watad A, Newton D, Bhan K, et al. T helper 2 IL-4/IL-13 dual blockade with Dupilumab is linked to some emergent T helper 17 - type diseases, including seronegative arthritis and Enthesitis/Enthesopathy, but not to humoral autoimmune diseases. J Invest Dermatol. 2022;142(10):2660-2667.